Brain: New leadership appointments
Biotechnology and enzyme expert Brain Biotech has announced appointments for two key leadership positions at its corporate site in Zwingenberg, headquarters and core biotechnology R&D campus of the international Brain Group.
Following the announcement in October 2022, to establish an independent division for Brain Biotech AG’s proprietary CRISPR technology, the company has now announced that Dr Alexander Pelzer will succeed Dr Michael Krohn as Head of Research & Development. Dr Krohn will now fully focus on his new leadership role with Akribion Genomics.
Dr Pelzer was previously Unit Head Enzymes & Biocatalysts at the company and has been with BRAIN Biotech for almost nine years. Dr Pelzer enjoyed a broad education in biocatalysis, microbiology and molecular biology at the Research Centre Juelich with a focus on industrial enzyme technology. In addition to his experience in relevant fields, he demonstrated strong leadership skills along his whole career path.
In addition, Dr Martin Langer will expand his current business development responsibilities and will be appointed Managing Director and Executive Vice President of the BioScience segment at the Zwingenberg site. Dr Langer was one of the first employees at Brain Biotech and accordingly has several decades of corporate experience. Alexander Pelzer and Martin Langer will take joint responsibility for further developing the R&D center in Zwingenberg into a customer-preferred provider for integrated biotechnology solutions.